Improved Gene Delivery to Adult Mouse Spinal Cord Through the Use of Engineered Hybrid Adeno-associated Viral Serotypes

Overview

Journal Gene Ther

Date 2017 Apr 26

PMID 28440798

Citations 9

Authors

J J Siu

N J Queen

W Huang

F Q Yin

X Liu

C Wang

D M McTigue

L Cao

Affiliations

Soon will be listed here.

Abstract

Adeno-associated viral (AAV) vectors are often used in gene therapy for neurological disorders because of its safety profile and promising results in clinical trials. One challenge to AAV gene therapy is effective transduction of large numbers of the appropriate cell type, which can be overcome by modulating the viral capsid through DNA shuffling. Our previous study demonstrates that Rec2, among a family of novel engineered hybrid capsid serotypes (Rec1~4) transduces adipose tissue with far superior efficiency than naturally occurring AAV serotypes. Here we assessed the transduction of adult spinal cord at two different doses of AAV vectors expressing green fluorescent protein (2 × 10 or 4 × 10 viral particles) via intraparenchymal injection at the thoracic vertebral level T9. In comparison with an equal dose of the currently preferable AAV9 serotype, Rec3 serotype transduced a broader region of the spinal cord up to ~1.5 cm longitudinally and displayed higher transgene expression and increased maximal transduction rates of astrocytes at either dose and neurons at the lower dose. These novel engineered hybrid vectors could provide powerful tools at lower production costs to manipulate gene expression in the spinal cord for mechanistic studies or provide potent vehicles for gene therapy delivery, such as neurotrophins, to the spinal cord.

Citing Articles

Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression.

Zhou X, Liu J, Xiao S, Liang X, Li Y, Mo F Int J Nanomedicine. 2024; 19:7691-7708.

PMID: 39099791 PMC: 11296317. DOI: 10.2147/IJN.S459905.

AAV Engineering for Improving Tropism to the Central Nervous System.

Ghauri M, Ou L Biology (Basel). 2023; 12(2).

PMID: 36829465 PMC: 9953251. DOI: 10.3390/biology12020186.

AAV vectors: The Rubik's cube of human gene therapy.

Pupo A, Fernandez A, Low S, Francois A, Suarez-Amaran L, Samulski R Mol Ther. 2022; 30(12):3515-3541.

PMID: 36203359 PMC: 9734031. DOI: 10.1016/j.ymthe.2022.09.015.

Viral strategies for targeting spinal neuronal subtypes in adult wild-type rodents.

Kaur J, Berg R Sci Rep. 2022; 12(1):8627.

PMID: 35606530 PMC: 9126985. DOI: 10.1038/s41598-022-12535-4.

Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice.

Queen N, Bates R, Huang W, Xiao R, Appana B, Cao L Mol Ther Methods Clin Dev. 2021; 20:409-422.

PMID: 33575433 PMC: 7848733. DOI: 10.1016/j.omtm.2020.12.011.

References

Snyder B, Gray S, Quach E, Huang J, Leung C, Samulski R . Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther. 2011; 22(9):1129-35. DOI: 10.1089/hum.2011.008. View

Zhang F, Jia S, Zheng S, Ding W . Celastrol enhances AAV1-mediated gene expression in mice adipose tissues. Gene Ther. 2010; 18(2):128-34. DOI: 10.1038/gt.2010.120. View

Yang B, Li S, Wang H, Guo Y, Gessler D, Cao C . Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther. 2014; 22(7):1299-1309. PMC: 4089005. DOI: 10.1038/mt.2014.68. View

Charbel Issa P, de Silva S, Lipinski D, Singh M, Mouravlev A, You Q . Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina. PLoS One. 2013; 8(4):e60361. PMC: 3621895. DOI: 10.1371/journal.pone.0060361. View

A Kotterman M, Schaffer D . Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014; 15(7):445-51. PMC: 4393649. DOI: 10.1038/nrg3742. View

Jimenez V, Munoz S, Casana E, Mallol C, Elias I, Jambrina C . In vivo adeno-associated viral vector-mediated genetic engineering of white and brown adipose tissue in adult mice. Diabetes. 2013; 62(12):4012-22. PMC: 3837045. DOI: 10.2337/db13-0311. View

Hordeaux J, Dubreil L, Deniaud J, Iacobelli F, Moreau S, Ledevin M . Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats. Gene Ther. 2015; 22(4):316-24. DOI: 10.1038/gt.2014.121. View

Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S . Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2014; 23(3):477-87. PMC: 4351452. DOI: 10.1038/mt.2014.210. View

Mizukami H, Mimuro J, Ogura T, Okada T, Urabe M, Kume A . Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors. Hum Gene Ther. 2006; 17(9):921-8. DOI: 10.1089/hum.2006.17.921. View

10.

Guo Y, Wang D, Qiao T, Yang C, Su Q, Gao G . A Single Injection of Recombinant Adeno-Associated Virus into the Lumbar Cistern Delivers Transgene Expression Throughout the Whole Spinal Cord. Mol Neurobiol. 2015; 53(5):3235-3248. PMC: 4671832. DOI: 10.1007/s12035-015-9223-1. View

11.

Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

12.

Dayton R, Wang D, Klein R . The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther. 2012; 12(6):757-66. PMC: 3361729. DOI: 10.1517/14712598.2012.681463. View

13.

Valori C, Ning K, Wyles M, Mead R, Grierson A, Shaw P . Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010; 2(35):35ra42. DOI: 10.1126/scitranslmed.3000830. View

14.

Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar A . Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. 2009; 17(7):1187-96. PMC: 2835208. DOI: 10.1038/mt.2009.71. View

15.

Huang W, McMurphy T, Liu X, Wang C, Cao L . Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector. Mol Ther. 2016; 24(6):1062-1069. PMC: 4923319. DOI: 10.1038/mt.2016.34. View

16.

Gray S, Matagne V, Bachaboina L, Yadav S, Ojeda S, Samulski R . Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther. 2011; 19(6):1058-69. PMC: 3129805. DOI: 10.1038/mt.2011.72. View

17.

Schuster D, Dykstra J, Riedl M, Kitto K, Belur L, McIvor R . Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 2014; 8:42. PMC: 4051274. DOI: 10.3389/fnana.2014.00042. View

18.

Burger C, Gorbatyuk O, Velardo M, Peden C, Williams P, Zolotukhin S . Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004; 10(2):302-17. DOI: 10.1016/j.ymthe.2004.05.024. View

19.

Liu X, Magee D, Wang C, McMurphy T, Slater A, During M . Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype. Mol Ther Methods Clin Dev. 2014; 1. PMC: 4224270. DOI: 10.1038/mtm.2013.8. View

20.

Foust K, Wang X, McGovern V, Braun L, Bevan A, Haidet A . Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010; 28(3):271-4. PMC: 2889698. DOI: 10.1038/nbt.1610. View